As Pfizer Inc. raced to develop a Covid-19 vaccine while the world looked on, the pharmaceutical giant was also quietly at work on remaking its brand.
On Tuesday, the company is launching its first major rebrand in decades with a new logo, an effort to highlight the company’s shift from a diversified health care giant to one more focused on creating prescription drugs and vaccines that prevent and cure disease.
“With Pfizer’s increased commitment to breakthrough science, now is the time to update our identity to reflect that reality,” Pfizer Chief Executive Officer Albert Bourla said in a statement.
The logo, 18 months in the making, replaces the oval, pill-like shape that had enclosed the Pfizer name since 1948 with a helix design to the left of the company name. It retains current elements, including the name, font and blue color. The company is promoting the new design with an ad campaign.
On technical fronts Pfizer Inc. RSI stood at 41.63 and currently stock is trading below all moving averages. So, SELL position can be taken with following target and stoploss:
TRADE SIGNAL – : Pfizer Inc. – SELL: 36.81, TARGET: 35.91, STOPLOSS : 37.14